Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 11, keine Gesamtzahl für „expected“
Suchtreffer
Begriffe & Kennungen
Nulojix · 4.5 · Belatacept is not expected to interrupt the enterohepatic recirculation of MPA. At a given dose of MMF, MPA ex
Eintrag öffnenOcrevus · 4.5 · No interaction studies have been performed, as no interactions are expected via cytochrome P450 enzymes, other
Eintrag öffnenOcrevus · 4.5 · No interaction studies have been performed, as no interactions are expected via cytochrome P450 enzymes, other
Eintrag öffnenOdefsey · 4.5 · Expected: Tenofovir alafenamide: AUC: ↑ Cmax: ↑ Inhibition of P-gp
Eintrag öffnenOdefsey · 4.5 · Expected: Tenofovir alafenamide: AUC: ↓ Cmax: ↓ Induction of P-gp
Eintrag öffnenOdefsey · 4.5 · Interaction not studied with tenofovir alafenamide. Co-administration of ketoconazole is expected to increase
Eintrag öffnenOnerji · 4.8 · In table 3 below, adverse reactions expected from Onerji are presented by System Organ Class (SOC) and frequen
Eintrag öffnenOprymea · 4.5 · 21 section 4.4), e.g. if antagonistic effects can be expected.
Eintrag öffnenOrgovyx · 4.5 · 13 Therapeutic dose for Abiraterone Expected: Expected: No clinically Orgovyx ↔ ↔ meaningful changes (CYP3A4 i
Eintrag öffnenOrgovyx · 4.5 · Apalutamide Therapeutic Expected: ↓ Expected: ↓ dose for Orgovyx In a clinical study , Orgovyx 120 QD (P-gp an
Eintrag öffnenOrgovyx · 4.5 · Darolutamide Therapeutic Expected: ↔ Expected: ↔ Darolutamide is a dose for weak inducer of Orgovyx CYP3A4. Ho
Eintrag öffnenOrgovyx · 4.5 · Enzalutamide Therapeutic Expected: ↔ Expected: ↔ Enzalutamide may dose for decrease (CYP3A4 Orgovyx induction)
Eintrag öffnenOrgovyx · 4.5 · Medicinal products Therapeutic Expected: ↓ Expected: ↓ that are combined P dose for gp and strong Orgovyx CYP3
Eintrag öffnenOrgovyx · 4.5 · Other medicinal Therapeutic Expected: ↑ Expected: ↑ products that are P-gp dose for inhibitor include (but Org
Eintrag öffnenOrgovyx · 4.5 · Therapeutic dose for Apalutamide Expected: Expected: Orgovyx ↔ ↔ (CYP2C8 and CYP3A4 substrate)
Eintrag öffnenOrgovyx · 4.5 · Therapeutic dose for Enzalutamide Expected: Expected: Orgovyx ↔ ↔ (CYP2C8 and CYP3A4 substrate)
Eintrag öffnenPantozol Control · 4.8 · Approximately 5% of patients can be expected to experience adverse reactions.
Eintrag öffnenPecFent · 4.8 · Summary of the safety profile Typical opioid adverse reactions are to be expected with PecFent. Frequently, th
Eintrag öffnenPifeltro · 4.5 · Doravirine is primarily metabolised by CYP3A, and medicinal products that induce or inhibit CYP3A are expected
Eintrag öffnenPifeltro · 4.5 · Expected: cobicistat-boosted PIs doravirine No dose adjustment is required. (darunavir, atazanavir) (Inhibitio
Eintrag öffnen